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To elucidate the modulatory role of histamine-degrading
enzymes in airway constrictor responses, human bron-
chial strips were studied under isometric conditions in
vitro. Pretreatment of tissues with the histamine N-me-
thyltransferase (HMT) inhibitor SKF 91488 specifically
potentiated the contractile responses to histamine, caus-
ing a leftward displacement of the concentration-
response curves, whereas the diamine oxidase inhibitor
aminoguanidine had no effect. This potentiation was at-
tenuated by mechanical removal of the epithelium. The
HMT activity was detected in the human bronchi, which
was less in the epithelium-denuded tissues than the epi-
thelium-intact tissues. These results suggest that HMT
localized to the airway epithelium may play a protective
role against histamine-mediated bronchoconstriction in
humans.
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Introduction
Histamine is released from mast cells and basophils
by a variety of stimuli including antigen cross-linked
IgE, and induces airway smooth muscle contraction,
microvascular leakage and mucus production." Thus
histamine probably plays a principal role in the
pathogenesis of immediate asthmatic responses. In
addition, because increased bronchial responsive-
ness to histamine is a well-characterized feature of
asthma, bronchial provocation by histamine has rou-
tinely been used to facilitate its diagnosis.
It has been known that histamine can be metabo-
lized by two major pathways in the body;4’5 50 to 70%
of histamine is metabolized by histamine N-
methyltransferase (HMT, EC 2.1.1.8), located in the
small intestine, liver, kidney and leukocytes, into N-
methylhistamine, and the remaining 30 to 45% is
metabolized by diamine oxidase (DAO, EC 1.4.3.6),
also called histaminase, located in intestinal mucosa,
placenta, liver, skin, kidney, neutrophils and
eosinophils, to imidazole acetic acid. Recent studies
on guinea-pig trachea showed that HMT but not
DAO decreases bronchoconstrictor responses to his-
tamine and antigen challenge. 6,: However, it remains
unknown which enzyme is responsible for the de-
gradation of histamine in the human airway and
where the enzyme is located. Therefore, human
bronchial strips were studied under isometric condi-
tions in vitro to elucidate the modulatory role of
histamine-degrading enzymes in the histamine-medi-
ated bronchoconstriction.
Materials and Methods
Preparation of tissues: Human lung tissues were
obtained from 23 patients at thoracotomies per-
formed because of carcinoma. After surgical removal,
pieces of macroscopically normal lung tissues were
rapidly immersed in Krebs-Henseleit solution con-
sisting of the following composition (in mM): NaCl,
118; KC1, 5.9; MgSO4, 1.2; CaC1,., 2.5; NaH,.PO, 1.2;
NaHCO3, 25.5; and D-glucose, 5.6; gassed with a
mixture of 95% O-5% CO,. at 37C. Cartilaginous
bronchi, 2 to 4 mm in internal diameter, were then
dissected free of parenchyma, fat and surrounding
connective tissues, and cut helically at a 45 pitch
to obtain bronchial strips measuring 2 to 3 mm in
width and approximately 20 mm in length. Between
two and eight strips were dissected from each speci-
men and mounted in 14 ml organ chambers contain-
ing Krebs-Henseleit solution aerated, with 95%
02-5% CO2 at 37C (pH 7.4, Pco,. 38 Torr, PO > 500
Torr). Contractile responses were continuously
measured isometrically with a force-displacement
transducer (Nihon Kohden, JB-652T, Tokyo, Japan)
and were recorded on a pen recorder (Nihon
Kohden, WT-685G). The tissues were allowed to
equilibrate for 60 min while they were washed with
Krebs-Henseleit solution every 15 min, and the rest-
ing tension was adjusted to 1 g. A contractile re-
sponse was determined as the difference between
peak tension developed and resting tension. All
experiments were conducted in the presence of
indomethacin (3 x 10-6M) and ranitidine (6 x 10-5M)
to avoid prostaglandin release and histamine
tachyphylaxis,
8 respectively.
Effects of histamine-degrading enzyme inbibitors:
Following the equilibration period, histamine was
added to the chamber in a cumulative manner at
concentrations ranging from 10-s to 10-3 M in half-
molar increments at 5 min intervals or 2 min after
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stable plateau was achieved, whichever was the
longer period. After establishing the first
concentration-response curves, tissues were washed
with Krebs-Henseleit solution until the tension
returned to the baseline level and, 60 min later,
SKF 91488 (10-4 M), an inhibitor of HMT,9’1
or aminoguanidine (10-4 M), an inhibitor of DAO,
11
was added. Twenty min later, the second
concentration-response curves for histamine were
generated in a similar manner. In a control experi-
ment, two successive concentration-response curves
for histamine were likewise generated without addi-
tion of an inhibitor.
To test whether the inhibition ofHMT activity also
alters the contractile responses to other spasmogenic
agonists, the effect of SKF 91488 (10-4 M) on the
concentration-response curves for acetylcholine and
KC1 were examined, with the same time sequence for
the contractile responses to histamine.
At the end of these experiments, each bronchial
strip was blotted on a gauze pad and weighed. Active
tensions were normalized for tissue weight and ex-
pressed as grams tension per gram of tissue weight.
To characterize the concentration-response curves,
the maximal contractile response (Emax) and the nega-
tive logarithm of molar concentration of agonist re-
quired to produce 50% of Emax (pD,) were determined
by linear regression analysis.
To assess concentration-dependent effects of his-
tamine-degrading enzyme inhibitors, contractile re-
sponses of bronchial strips to 10-5 M histamine were
determined in the absence and presence of either
SKF 91488 or aminoguanidine (10-
to 10-3 M). In this
experiment, after determining the first responses to
histamine, tissues were washed, applied with a single
concentration of either inhibitor and, 20 min later,
the second responses to histamine were determined.
To assess whether the modulation of the contrac-
tile responses to histamine by SKF 91488 was asso-
ciated with the epithelium, concentration-response
curves for histamine were constructed in the absence
and presence of SKF 91488 (10.4 M) in tissues with
the epithelial cells denuded. Bronchial strips were
gently rubbed off their luminal surface with a moist
cotton swab, and confirmation of the successful
removal of the epithelium was histologically per-
formed in randomly selected tissues.
Measurement ofHMT activity: The activity of HMT
was measured in bronchial tissues with and without
epithelium according to the method by Fukuda et
al.’ Briefly, excised bronchi were homogenized in a
glass homogenizer, with four volumes of ice-cold
phosphate buffered saline (0.05 M, pH 7.4) contain-
ing 1 mM dithiothreitol and 1% polyethyleneglycol.
The homogenate was centrifuged at 4C (120 000 xg,
1 h), and the supernatant was dialysed three times for
8 h against 100 volumes of the buffer. The reaction
ofHMT was carried out at 37C in 0.5 ml of a mixture
of 0.1 ml of the supernatant, 0.3 ml of 0.1 M phos-
phate buffered saline containing 0.1 mM pargyline
and 0.1 mM aminoguanidine (pH 7.4), 0.05 ml of
1 mM histamine and 0.05 ml of S-adenosyl-t-
methionine. After incubation, N*-methylhistamine
was separated from histamine by high-performance
liquid chromatography on a weak cation exchanger
(Toyo-Soda Co., TSKgel CM2SW, Tokyo), with
37.5 mM citric acid, 1.25% imidazole and 20%
acetonitrile, with the mobile phase at a flow rate of
1.0 ml/min. The fluorescence intensity of the reaction
mixture was then measured using a post-column
derivatization with o-phthalaldehyde and 2-
mercaptoethanol, and the HMT activity was ex-
pressed as pmol of N-methylhistamine formed per h
per mg of protein as determined by the method of
Lowry et al.
Drugs: The following drugs were used: histamine
diphosphate, indomethacin, acetylcholine chloride,
KCl, aminoguanidine (Sigma Chemical Co., St Louis,
MO); and ranitidine (Glaxo Co., Tokyo). SKF 91488
(S-[4[(N,N-dimethylamino)-butyl] isothiourea) was a
gift from Smith Kline Co. (Philadelphia, PA).
Statistics: All values were expressed as means + S.E.
Comparative statistical analysis was performed using
ANOVA followed by either Tukey’s test for multiple
comparisons or by Student’s t-test; n refers to the
number of preparations, andp < 0.05 was considered
statistically significant.
Results
Muscle contraction: As demonstrated in Fig. 1, in
the control experiment both the Emax and the pD,
values of the second histamine concentration-
response curves of human bronchial strips were not
significantly different from those of the first
concentration-response curves. Thus, the histamine-
induced tachyphylaxis was not observed in the pres-
ence of indomethacin and ranitidine. Addition of SKF
91488 (10-4 M) and aminoguanidine (10-4 M) did not
alter the resting tension. Pretreatment of tissues with
SKF 91488 potentiated the contractile responses to
histamine, causing a leftward displacement of the
histamine concentration-response curves with the
pD,. values being increased from 5.0 +_ 0.1 to 5.8 +_ 0.3
(p<0.01, n 10) but theE values remained un-
changed. On the other hand, aminoguanidine also
tended to potentiate the contractile responses to
histamine, but the change in the pD, values did not
reach a significant level (5.0_+0.2 to 5.2_+0.3,
p < 0.05, n 9).
The SKF 91488-induced potentiation of the con-
tractile responses to 10-5 M histamine was concentra-
tion dependent, with a threshold concentration and
the maximal increase from the baseline value being
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FIG. 1. Effects of SKF 91488 (10 M) and aminoguanidine (10 M) on
contractile responses of human bronchial strips to histamine. After estab-
lishing baseline responses to histamine (open circles), tissues were
washed, either inhibitor was added and, 20 min later, the second
concentration-response curves were generated (closed circles). Tissues
without addition of an inhibitor served as control experiments. Values are
expressed as percentage of the maximal baseline response. Each point
represents mean + S.E.; n= 10 for control and SKF 91488, and n= 9 for
aminoguanidine.
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FIG. 2. Concentration dependent effects of SKF 91488 and aminoguanidine
on contractile responses to 10 M histamine. Values are expressed as
percent of the baseline responses obtained before the addition of an
inhibitor. Data are means+S.E.; n=8 for each column. *p<0.05,
**p < 0.01, ***p < 0.001, significantly different from baseline values.
Table 1. Effect of SKF 91488 on contractile responses of human
bronchail strips
Agonist
pD Enax
Control SKF 91488 Control SKF 91488 CR
(10-4 M) (10- M)
Histamine 5.0 + 0.1
Acetylcholine 6.2 + 0.2
KCI 1.9 + 0.1
5.8 + 0.3** 13.2 + 2.2 13.8 + 3.1 6.3
6.4+0.3 11.8+1.9 12.6+2.0 1.6
1.9+0.2 10.7+1.9 11.5+2.6 1.0
pD2, negative logarithm of molar concentration of the agonist re-
quired to produce a half-maximal effect; Emax, maximal contraction
as expressed by g/g tissue; CR, concentration ratio as determined
by antilog (pD2 in the presence of SKF 91488-control pD).
Data are means + S.E.; n 10 for histamine and acetylcholine and
n 11 for KCI. p < 0.01, significantly different from control values.
10 M and 48.3 _+ 4.9% (p < 0.001, n 8), respec-
tively, whereas aminoguanidine caused a significant
increase only at 10-3 M by 12.5 -+ 3.1% (p < 0.05,
n 8, Fig. 2).
In contrast to the effect on histamine-induced
contraction, pretreatment of tissues with SKF 91488
(10-4M) had no effect on the contractile responses to
other spasmogenic agonists, acetylcholine and KCl
(Table 1).
In bronchial strips with the epithelium removed,
SKF 91488 (10-4 M) still potentiated the contractile
responses to histamine, the pD values being in-
creased from 5.6 _+ 0.3 to 6.1 _+ 0.2 (p< 0.05, n 11,
Fig. 3). However, the magnitude of the leftward shift
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FIG. 3. Effect of SKF 91488 (10 M) on contractile responses to histamine
in bronchial strips with the epithelium removed. After establishing baseline
responses to histamine (open circles), SKF 91488 was added and the
second concentration-response curves were generated (closed circles).
Values are expressed as percent of the maximal baseline response. Each
point represents mean + S.E.; n 11.
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FIG. 4. Histamine N-methyltransferase (HMT) activity in human bronchial
tissues. Activity of the enzyme was measured by high-performance liquid
chromatography based on post-column derivatization with o-
phthalaldehyde. Data are means + S.E.; n 11 for epithelium-intact tissues
and n 12 for epithelium-denuded tissues. *p < 0.05, significantly different
from values for epithelium-intact tissues.
of the concentration-response curves was small com-
pared with the epithelium-intact tissues; SKF 91488
potentiated histamine-induced contraction by 6.3-
fold in epithelium-intact strips and by 3.2-fold in
epithelium-denuded tissues.
Tissue HMT activity: The activity of HMT in human
bronchi determined by high-performance liquid
chromatography was 920 _+ 230 pmol/mg protein/h
(n 11) for the epithelium-intact tissues and 280 + 70
pmol/mg protein/h (n 12) for the tissues without
epithelium. There was a significant difference be-
tween these values (p< 0.05, Fig. 4).
Discussion
The present in vitro studies demonstrate that HMT
probably localized to human airway epithelium may
play a protective role in the histamine-mediated
bronchoconstriction through the degradation of his-
tamine to its inactive metabolite. This notion is based
on the following findings. First, pretreatment of
bronchial strips with the HMT inhibitor SKF 914889,1
potentiated the histamine-induced contraction in a
concentration dependent fashion without affecting
contractile responses to other spasmogenic agonists
including acetylcholine and KCl; secondly, the mag-
nitude of the SKF-induced leftward displacement of
histamine concentration-response curves was sig-
nificantly less in bronchial strips with the epithelium
mechanically removed than in the epithelium-intact
tissues; and thirdly, the activity of HMT was meas-
ured by high-performance liquid chromatography
using post-column derivatization with o-
phthalaldehyde and it was found that the HMT activ-
ity of human bronchial tissues was greatly decreased
by removal of the epithelium.
It has been known that histamine is metabolized
by two major enzymes, HMT and DAO, located on
a variety of mammalian tissues and inflammatory
cells. TM HMT catalyses methyl transfer from S-
adenosyl-t-methionine to histamine to form N-
methylhistamine, which is further metabolized by
monoamine oxidase to N-methylimidazole acetic
acid, 15 and DAO also metabolizes histamine to N-
methylimidazole acetic acid. 16 In the present study, it
was found that, in contrast to the effect of SKF 91488,
aminoguanidine at concentrations sufficient to in-
hibit DAO activity
11 had little effect on the contractile
responses to histamine. Therefore, histamine may be
metabolized principally through the HMT pathway in
human airways, as is also true in the brain. 17
The airway epithelium has been shown to inhibit
bronchoconstrictor responses to a variety of stimuli
by releasing epithelium-derived relaxing factor,
which is not a product of arachidonic acid and is not
nitric oxide,
18-2 and by metabolizing tachykinins
with neutral endopeptidase.
2 Concerning the hista-
mine metabolism, there are conflicting reports on
guinea-pig tracheal epithelium. Lindstr6m et al.
showed the aminoguanidine-induced potentiation of
the contractile responses to histamine, but Ohrui et
al. recently reported the lack of aminoguanidine’s
effect and showed the presence of HMT activity and
its mRNA in the epithelium by in situ hybridization,
and Sekizawa et al. reported a similar finding in
antigen-induced bronchoconstriction in vivo. The
present findings on human bronchi were in agree-
ment with the latter two reports. Although DAO
activity was not measured, the results of the muscle
bath experiments suggest that the epithelial HMT
activity is more important than DAO in limiting the
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biological actions of histamine in human airways. In
tissues without epithelium, the,HMT activity was still
present and the SKF 91488-induced potentiation of
the contractile responses to histamine was small but
still significant. These findings suggest that HMT
localized to other cell types such as endothelial cells
could also contribute to histamine degradation.
In conclusion, the histamine-degrading enzyme
HMT in the airway epithelium may play a modulatory
role in the bronchoconstriction in human airways
through a metabolism of histamine. The authors
therefore speculate that airway hyperresponsiveness
to histamine in asthmatic subjects could be due, at
least in part, to the epithelial damage-associated loss
of HMT activity.
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